nach oben

International Journal of Clinical Oncology

Erschienen in:

28.11.2019 | Original Article

Predictive value of ¹⁸F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy

verfasst von: Kimitaka Akaike, Koichi Saruwatari, Seitaro Oda, Shinya Shiraishi, Hiroshi Takahashi, Shohei Hamada, Shinji Iyama, Yuko Horio, Yusuke Tomita, Sho Saeki, Shinichiro Okamoto, Hidenori Ichiyasu, Kazuhiko Fujii, Takuro Sakagami

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

We examined whether fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) performed before chemotherapy could predict the onset of acute exacerbation of interstitial lung disease (AE-ILD) in patients with lung cancer and ILD treated with chemotherapy.

Methods

Thirty-three patients with lung cancer and ILD who underwent ¹⁸F-FDG PET/CT and were treated with chemotherapy at Kumamoto University Hospital between April 2006 and March 2018 were retrospectively analyzed. The maximum standardized uptake value (SUV_max) of interstitial lesions was measured to quantify the background ILD activity. A prediction model of AE-ILD was developed using logistic regression analyses for the SUV_max, and receiver operating characteristic (ROC) curve analyses were conducted.

Results

Among the 33 patients, 7 experienced AE-ILD. The SUV_max of contralateral interstitial lesions was significantly higher in patients with vs. without AE-ILD (median SUV_max: 2.220 vs. 1.795, P = 0.025). Univariable logistic regression analyses showed that the SUV_max of contralateral interstitial lesions trended towards being significantly associated with the onset of AE-ILD [odds ratio: 8.683, 95% confidence interval (CI) 0.88–85.83, P = 0.064]. The area under the ROC curve of the SUV_max for predicting AE-ILD was 0.780 (95% CI 0.579–0.982, P = 0.025). The optimal cut-off value for SUV_max was 2.005, with sensitivity and specificity values of 0.857 and 0.769, respectively.

Conclusions

The SUV_max of contralateral interstitial lesions in ¹⁸F-FDG PET/CT images might be useful for predicting the onset of AE-ILD in patients with lung cancer and ILD treated with chemotherapy.

Nur mit Berechtigung zugänglich

Ozawa Y, Suda T, Naito T et al (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology (Carlton, Vic) 14(5):723–728. https://doi.org/10.1111/j.1440-1843.2009.01547.x CrossRef

Tomassetti S, Gurioli C, Ryu JH et al (2015) The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 147(1):157–164. https://doi.org/10.1378/chest.14-0359 CrossRefPubMed

Minegishi Y, Takenaka K, Mizutani H et al (2009) Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med (Tokyo, Japan) 48(9):665–672CrossRef

Shukuya T, Ishiwata T, Hara M et al (2010) Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res 30(10):4357–4361PubMed

Kenmotsu H, Naito T, Kimura M et al (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6(7):1242–1246. https://doi.org/10.1097/JTO.0b013e318216ee6b CrossRefPubMed

Kakiuchi S, Hanibuchi M, Tezuka T et al (2017) Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: a feasibility of S-1. Respir Investig 55(2):145–152. https://doi.org/10.1016/j.resinv.2016.10.008 CrossRefPubMed

Enomoto Y, Inui N, Kato T et al (2016) Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer (Amsterdam, Netherlands) 96:63–67. https://doi.org/10.1016/j.lungcan.2016.03.017 CrossRef

Chao F, Zhang H (2012) PET/CT in the staging of the non-small-cell lung cancer. J Biomed Biotechnol 2012:783739. https://doi.org/10.1155/2012/783739 CrossRefPubMedPubMedCentral

Justet A, Laurent-Bellue A, Thabut G et al (2017) [(18)F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res 18(1):74. https://doi.org/10.1186/s12931-017-0556-3 CrossRefPubMedPubMedCentral

10.

Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68. https://doi.org/10.1164/rccm.201807-1255ST CrossRef

11.

Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. https://doi.org/10.1164/rccm.2009-040GL CrossRefPubMedPubMedCentral

12.

Groves AM, Win T, Screaton NJ et al (2009) Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 50(4):538–545. https://doi.org/10.2967/jnumed.108.057901 CrossRefPubMed

13.

Brown RS, Leung JY, Kison PV et al (1999) Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 40(4):556–565PubMed

14.

van Baardwijk A, Dooms C, van Suylen RJ et al (2007) The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer (Oxford, England 1990) 43(9):1392–1398. https://doi.org/10.1016/j.ejca.2007.03.027 CrossRef

15.

El-Chemaly S, Malide D, Yao J et al (2013) Glucose transporter-1 distribution in fibrotic lung disease: association with [(1)(8)F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization. Chest 143(6):1685–1691. https://doi.org/10.1378/chest.12-1359 CrossRefPubMed

16.

Andrianifahanana M, Hernandez DM, Yin X et al (2016) Profibrotic up-regulation of glucose transporter 1 by TGF-beta involves activation of MEK and mammalian target of rapamycin complex 2 pathways. FASEB J 30(11):3733–3744. https://doi.org/10.1096/fj.201600428R CrossRefPubMedPubMedCentral

17.

Bergeron A, Soler P, Kambouchner M et al (2003) Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J 22(1):69–76CrossRef

18.

Lodge MA (2017) Repeatability of SUV in Oncologic (18)F-FDG PET. J Nucl Med 58(4):523–532. https://doi.org/10.2967/jnumed.116.186353 CrossRefPubMedPubMedCentral

Titel: Predictive value of 18F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy
verfasst von: Kimitaka Akaike
Koichi Saruwatari
Seitaro Oda
Shinya Shiraishi
Hiroshi Takahashi
Shohei Hamada
Shinji Iyama
Yuko Horio
Yusuke Tomita
Sho Saeki
Shinichiro Okamoto
Hidenori Ichiyasu
Kazuhiko Fujii
Takuro Sakagami
Publikationsdatum: 28.11.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 4/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01584-x

Springer Medizin

Predictive value of ¹⁸F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy